2013 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/19/13Verastem Announces Addition to the NASDAQ Biotechnology Index
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 19, 2013-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition to the NASDAQ Biotechnology Index will become effective upon market open on December 23, 2013. The NASDAQ Biotechnology Index is designed to... 
Printer Friendly Version
12/10/13Verastem Initiates Clinical Trial of Dual mTOR/PI3K Inhibitor
Phase 1 dose escalation and schedule finding trial in solid tumors and lymphomas CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 10, 2013-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the initiation of a Phase 1 trial of VS-5584, a dual mTORC1/2 and PI3K inhibitor, in patients with advanced solid tumors or lymphoma. “Initiation of... 
Printer Friendly Version
11/26/13Verastem to Present at Upcoming Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 26, 2013-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that the Company will present at upcoming scientific and investor conferences. The presentation details are as follows: 6th Annual 2013 Deutsche Bank BioFEST on Monday, December 2, 2013 at 1:40 p.m. ET at The Four Seasons Hotel in Boston, MA... 
Printer Friendly Version
11/12/13Verastem Reports Third Quarter 2013 Financial and Corporate Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 12, 2013-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today reported financial results for the third quarter ended September 30, 2013, and also provided an overview of certain corporate accomplishments and plans. “We continue to execute on our development plans and have made significant and rapid progress in ... 
Printer Friendly Version
10/31/13Verastem Names Jose Baselga, M.D., Ph.D. as Senior Medical Advisor
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 31, 2013-- Verastem, Inc., (NASDAQ:VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that Jose Baselga, M.D., Ph.D., has been named Senior Medical Advisor to the company. “Research to develop new therapies targeting cancer stem cells is very exciting,” said Jose Baselga, M.D., Ph.D., Verastem Senior Medical Advisor and Physician-... 
Printer Friendly Version
10/24/13Verastem Announces Presentations at the 2013 World Conference on Lung Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 24, 2013-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced scheduled poster presentations at the 2013 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer which is taking place October 27-30, 2013 in Sydney, Australia. ... 
Printer Friendly Version
10/21/13Verastem Announces Presentation of VS-6063 Clinical and Preclinical Study Results at the 2013 AACR-NCI-EORTC International Conference
Results Support Continued Development of VS-6063 Across Multiple Tumor Types CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 21, 2013-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of defactinib (VS-6063) in combination with paclitaxel in patients with ovarian cancer that were pr... 
Printer Friendly Version
10/15/13Verastem Executives Featured at Boston-Area Biotechnology Events
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 15, 2013-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that President/Chief Executive Officer, Robert Forrester, Chief Medical Officer, Dr. Joanna Horobin, and Head of Research, Dr. Jonathan Pachter, will participate in upcoming life science panel discussions later this month. The details of the events ... 
Printer Friendly Version
10/10/13Verastem Announces Presentations at the 2013 AACR-NCI-EORTC International Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 10, 2013-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced scheduled poster presentations at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics which is taking place October 19-23, 2013 in Boston. Title: Phase 1/1b Study of the FAK Inhibitor Defactinib (VS... 
Printer Friendly Version
09/26/13Verastem Initiates Phase 2 Trial of Defactinib in Lung Cancer
Study Focuses on Patients with KRAS-mutated Non-Small Cell Lung Cancer CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 26, 2013-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the initiation of a Phase 2 trial of defactinib (VS-6063), a potent inhibitor of focal adhesion kinase (FAK), in KRAS-mutated non-small cell lung cancer (NSCLC). ... 
Printer Friendly Version
09/24/13Verastem Initiates Trial of Defactinib in Japan
Study Represents First-in-Asia Use of Lead FAK Inhibitor to Target Cancer Stem Cells CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 24, 2013-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the initiation of a Phase 1 trial of defactinib (VS-6063), a potent inhibitor of focal adhesion kinase (FAK), in Japanese patients with advanced solid tumors. ... 
Printer Friendly Version
09/19/13Verastem Reports on Ongoing Trials at Cancer Advance at Harvard Medical School
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 19, 2013-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, presented data today at Cancer Advance at Harvard Medical School. Members of the Company’s management team participated in multiple panel discussions, and two posters describing ongoing clinical trials were presented. Verastem presented posters on the ongo... 
Printer Friendly Version
09/18/13Verastem to Present at Upcoming Scientific and Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 18, 2013-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the Company will present at multiple upcoming scientific and investor conferences. The Verastem presentation information is as follows: Advances in Ovarian Cancer Research: From Concept to Clinic Conference Date: September 18-21,... 
Printer Friendly Version
09/10/13Verastem Initiates COMMAND: A Registration-Directed Trial of Defactinib in Patients with Mesothelioma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 10, 2013-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the initiation of COMMAND (Control Of Mesothelioma with MAiNtenance Defactinib). COMMAND is a registration-directed trial of lead cancer stem cell inhibitor defactinib (VS-6063) in patients with malignant pleural mesothelioma, a highly aggressive f... 
Printer Friendly Version
09/03/13Verastem to Present at Upcoming Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 3, 2013-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that the members of the management team will present at upcoming conferences. The presentation details are as follows: Rodman & Renshaw® Annual Global Investment Conference on Tuesday, September 10, 2013 at 10 a.m. ET at the Millennium B... 
Printer Friendly Version
08/15/13Verastem Issued U.S. Patent Covering VS-4718 Composition of Matter
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 15, 2013-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,501,763 claiming composition of matter for VS-4718, the Company’s novel, small molecule inhibitor of cancer stem cells through blockade of focal adhesion kinase (FAK). The U.S. patent gra... 
Printer Friendly Version
08/13/13Verastem Reports Second Quarter 2013 Financial and Corporate Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 13, 2013-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today reported financial results for the second quarter ended June 30, 2013, and also commented on certain corporate accomplishments and plans. “We have made significant progress in our mission to create drugs targeting cancer stem cells and to enable a more dur... 
Printer Friendly Version
08/07/13Verastem to Present at the 2013 Wedbush Life Sciences Management Access Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 7, 2013-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that the Company will present at the upcoming Wedbush Life Sciences Management Access Conference on Wednesday, August 14th at 3:40 p.m. Eastern Time. The conference will take place at Le Parker Meridien hotel in New York City. A webcast of the pr... 
Printer Friendly Version
07/24/13Verastem Receives Orphan Drug Designation from the U.S. FDA for Defactinib in Mesothelioma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 24, 2013-- Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that lead cancer stem cell inhibitor, VS-6063 (defactinib), has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for use in the treatment of mesothelioma, a rare form of lung cancer. The designation is designed to encourage the... 
Printer Friendly Version
07/23/13Defactinib in Combination with Weekly Paclitaxel Achieves a Complete Response in Platinum-Resistant Ovarian Cancer
Interim results from an ongoing Phase 1/1b trial of VS-6063 (defactinib) in combination with weekly paclitaxel CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 23, 2013-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the confirmation of a complete response in an ongoing trial of VS-6063 (defactinib) in combination with weekly paclitaxel. A... 
Printer Friendly Version
07/22/13Verastem Announces Closing of Public Offering and Exercise of Option to Purchase Additional Shares
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 22, 2013-- Verastem, Inc., (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the closing of a $63.8 million underwritten public offering of 4,255,000 shares of common stock, including 555,000 shares of common stock which were issued pursuant to the exercise of the underwriters' option to purchase additional shares, at a price of... 
Printer Friendly Version
07/17/13Verastem Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 17, 2013-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the pricing of its previously announced underwritten public offering of 3,700,000 shares of its common stock, offered at a price of $15.00 per share to the public. The net proceeds to Verastem from this offering are expected to be approximately $51.9 mil... 
Printer Friendly Version
07/16/13Verastem Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 16, 2013-- Verastem, Inc., (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actu... 
Printer Friendly Version
07/11/13Verastem Presents Results and Updated Development Plans at Annual Research and Development Day
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 11, 2013-- Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today hosted its annual Research and Development Day at the Harvard Club in New York, NY. Members of the Verastem leadership team provided an overview of the Company’s development programs targeting cancer stem cells through the inhibition of focal adhesi... 
Printer Friendly Version
07/02/13Verastem to Present at the 8th Annual JMP Securities Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 2, 2013-- Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that the Company, will present at the upcoming 8th Annual JMP Securities Healthcare Conference on Wednesday, July 10th at 11:30am ET. The conference will take place at The St. Regis Hotel in New York City. A webcast of the presentation can be acc... 
Printer Friendly Version
06/27/13Verastem Successfully Completes Phase 1 Stage of Combination Trial of Cancer Stem Cell Inhibitor VS-6063 and Paclitaxel
--Four of six patients continuing on study and significant reduction in CA-125 observed-- --Phase 1b portion of the study is now open for enrollment-- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 27, 2013-- Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the completion of the dose escalation stage of VS-6063 and paclitaxel in a Phase 1/1b tria... 
Printer Friendly Version
06/26/13Verastem Initiates Phase 1 Clinical Trial of VS-4718 in Patients with Advanced Cancer
--VS-4718 is the Second Cancer Stem Cell Inhibitor to Enter Clinical Development-- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 26, 2013-- Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the initiation of a Phase 1 trial of VS-4718, a novel, small molecule inhibitor of focal adhesion kinase (FAK), in patients with advanced cancer. Resea... 
Printer Friendly Version
06/25/13Verastem Announces Annual Research and Development Day and Webcast
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 25, 2013-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that the Company will host its annual Research and Development Day on Thursday, July 11, 2013 from 12:30 – 3:30 pm at the Harvard Club in NY, NY. The company will discuss recent advances and clinical plans for their programs targeting cancer ste... 
Printer Friendly Version
06/13/13Verastem Receives Orphan Medicinal Product Designation from the European Commission for VS-6063 in Mesothelioma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 13, 2013-- Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that VS-6063 has received orphan medicinal product designation from the European Commission for use in mesothelioma. The designation is to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases. ... 
Printer Friendly Version
06/06/13Verastem Appoints Robert Forrester as Chief Executive Officer
-- Christoph Westphal, M.D., Ph.D., to Transition to Executive Chairman as of July 1, 2013 -- --Conference Call Scheduled for 8:45am ET on Thursday, June 6-- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 6, 2013-- Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that Robert Forrester, President and Chief Operating Officer, will be named Pr... 
Printer Friendly Version
06/03/13Verastem Hosts Dr. Dean Fennell for a Mesothelioma Briefing at ASCO
-Webcast replay now available- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 3, 2013-- Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, held a mesothelioma briefing session on Saturday morning with Dr. Dean Fennell at the annual American Society of Clinical Oncology meeting in Chicago, IL. Dr. Fennell is the Chair of Thoracic Medical Oncology at the Unive... 
Printer Friendly Version
05/23/13Verastem to Present at the 2013 ASCO Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 23, 2013-- Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the research and development team will present the clinical design for an ongoing study of VS-6063 and preclinical data on the dual PI3K/mTOR inhibitor VS-5584 at the American Society of Clinical Oncology Annual Meeting being held May 31 – June... 
Printer Friendly Version
05/21/13Verastem to Present at Upcoming Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 21, 2013-- Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will be presenting at several upcoming conferences. The presentation details are as follows: ChinaBio Partnering Forum on May 29, 2013, at 4:30pm local time at the Shangri-La Hotel in Beijing, China ... 
Printer Friendly Version
05/14/13Jack Green Joins Verastem as Chief Financial Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 14, 2013-- Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the appointment of John “Jack” Green as Chief Financial Officer. Mr. Green was the former Chief Financial Officer of GTC Biotherapeutics and has held multiple senior finance roles in public and private biotechnology companies over the course of his career. ... 
Printer Friendly Version
05/09/13Verastem Reports First Quarter 2013 Financial and Corporate Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 9, 2013-- Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today reported financial results for the quarter ended March 31, 2013, and also commented on certain corporate accomplishments and plans. “During the first quarter we made key strides in advancing our development programs targeting cancer stem cells,” said Christ... 
Printer Friendly Version
05/08/13Verastem to Present at Upcoming Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 8, 2013-- Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will be presenting at several upcoming conferences. The presentation details are as follows: UBS Global Healthcare Conference on May 22, 2013, at 8:30am ET at the Sheraton New York Hotel in New York, NY ... 
Printer Friendly Version
04/17/13Verastem to Present at Upcoming Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 17, 2013-- Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will be presenting at several upcoming conferences. The presentation details are as follows: 2013 BIO International Convention Business Forum on April 22, 2013, at 2:15pm CT in the Chicago Bears room of M... 
Printer Friendly Version
04/03/13Verastem to Present Scientific Results at the 2013 AACR Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 3, 2013-- Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the presentation of preclinical data at the American Association for Cancer Research annual meeting being held April 6 - 10, 2013, at the Walter E. Washington Convention Center in Washington, DC. Veraste... 
Printer Friendly Version
03/28/13Verastem to Present at Upcoming Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 28, 2013-- Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will be presenting at several upcoming conferences. The presentation details are as follows: Boston BD Biotech Conference on April 2-3, 2013, at the Four Seasons ... 
Printer Friendly Version
03/27/13Verastem Reports Year-End 2012 Financial Results
--Advancing Clinical Development Programs Targeting Cancer Stem Cells through FAK and PI3K/mTOR Inhibition-- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 27, 2013-- Verastem, Inc., (NASDAQ: VSTM), a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, reported financial results for the year ended December 31, 2012, and also commented on corporate accomplis... 
Printer Friendly Version
03/13/13Verastem Announces Timing for Year-End 2012 Financial Results, Webcast and Conference Call
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 13, 2013-- Verastem, Inc., (NASDAQ: VSTM), a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that financial results for the year ended December 31, 2012, will be released before the market opens on Wednesday, March 27, 2013. The Verastem management team will host a conference call discussing the Company'... 
Printer Friendly Version
03/06/13Stephen Sherwin, M.D., Joins Verastem Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2013-- Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the appointment of Stephen Sherwin, M.D., to the Board of Directors. “Steve has a wealth of biopharmaceutical and drug development expertise,” said Christoph Westphal, M.D., Ph.D., Chairman and CEO of ... 
Printer Friendly Version
02/27/13Verastem Cofounders to Present at MIT Technology Breakfast on Breakthrough Discoveries in Cancer Stem Cells
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 27, 2013-- Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that Robert Weinberg, Ph.D., Verastem scientific cofounder and chair of the Scientific Advisory Board, and Christoph Westphal, M.D., Ph.D., Verastem cofounder, Chairman and CEO, will present at the MIT Technology ... 
Printer Friendly Version
02/26/13Verastem to Present at Upcoming Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 26, 2013-- Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will be presenting at several upcoming conferences. The presentation details are as follows: Cowen and Company 33rd Annual Healthcare Conference on Ma... 
Printer Friendly Version
02/20/13Verastem to Present at Keystone Symposia on PI3 Kinase
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 20, 2013-- Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the presentation of data at the Keystone Symposia on “PI3-Kinase and Interplay with Other Signaling Pathways” being held February 24 – March 1, 2013, in Keystone, Colorado. The details of the Verast... 
Printer Friendly Version
02/14/13Verastem Files for Orphan Disease Status for VS-6063 in Mesothelioma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 14, 2013-- Verastem, Inc., (NASDAQ: VSTM), a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the filing of orphan drug designation for VS-6063. Verastem is seeking orphan drug designation in the US and the EU for the use of VS-6063 in mesothelioma. VS-6063 is anticipated to enter a potenti... 
Printer Friendly Version
02/06/13Scientific Data on PI3K/mTOR Inhibitor VS-5584 Published in Molecular Cancer Therapeutics
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 6, 2013-- Verastem, Inc., (NASDAQ: VSTM), a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the publication of data for VS-5584 in Molecular Cancer Therapeutics. VS-5584 is a potent and selective inhibitor of the PI3K/mTOR pathway. Previous research has described a central role of this pathway in... 
Printer Friendly Version
02/05/13Verastem Initiates Phase 1/1b Clinical Trial of VS-6063 Plus Paclitaxel for Patients with Ovarian Cancer
--VS-6063 Kills Cancer Stem Cells through Potent Inhibition of Focal Adhesion Kinase-- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 5, 2013-- Verastem, Inc., (NASDAQ: VSTM), a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the initiation of a Phase 1/1b trial of VS-6063 in combination with paclitaxel for the treatment of advanced ov... 
Printer Friendly Version
02/04/13Verastem to Present at Upcoming Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 4, 2013-- Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will be presenting at several upcoming conferences. The presentation details are as follows: Molecular Medicine Tri-Conference symposium on Targeting Cancer Ste... 
Printer Friendly Version
01/22/13Verastem Promotes Chief Operating Officer Robert Forrester to President
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 22, 2013-- Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, promoted Robert Forrester to President in addition to Chief Operating Officer. “Verastem has rapidly progressed through Robert’s dedication and outstanding execution across all aspects of the Company,” said Christop... 
Printer Friendly Version
01/09/13Verastem Enters Biomarker Agreement with LabCorp for Cancer Stem Cell Agent Companion Diagnostic
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 9, 2013-- Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, entered an agreement with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) to validate biomarkers for its lead focal adhesion kinase (FAK) inhibitor VS-6063 in the development of an applicable companion ... 
Printer Friendly Version
01/03/13Verastem to Present at East/West CEO and J.P. Morgan Healthcare Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 3, 2013-- Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will be presenting at several upcoming conferences. The presentation details are as follows: East/West CEO Conference on Sunday, January 6, 2013, at the Four ... 
Printer Friendly Version